Ribonucleic acid in situ hybridization is a more sensitive method than immunohistochemistry in detection of thyroid transcription factor 1 and napsin a expression in lung adenocarcinomas

Archives of Pathology and Laboratory Medicine

Volumn 140, Issue 4, 2016, Pages 332-340

  Shi, Jianhui ^a   Liu, Haiyan ^a   Ma, Xiao Jun ^b   Chen, Zongming ^a   He, Ming Xiao ^b   Luo, Yuling ^b   Lin, Fan ^a  

^a GEISINGER MEDICAL CENTER   (United States)

^b Advanced Cell Diagnostics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC PROTEINASE; NAPSA PROTEIN, HUMAN; NUCLEAR PROTEIN; RNA; THYROID NUCLEAR FACTOR 1; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PROCEDURES; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ASPARTIC ACID ENDOPEPTIDASES; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG; LUNG NEOPLASMS; NUCLEAR PROTEINS; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION FACTORS;

EID: 84964047629     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2014-0644-OA     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Sholl LM. Biomarkers in lung adenocarcinoma: a decade of progress. Arch Pathol Lab Med. 2015;139(4):469-480.
3. Bernicker E. Biomarker testing in non-small cell lung cancer: a clinician's perspective. Arch Pathol Lab Med. 2015;139(4):448-450.
4. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139.
5. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184-2191.
6. Dogan S, Shen R, Ang DC, et al. Molecular epidemiology of EGFR and KRAS mutations in 3, 026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012;18(22):6169-6177.
7. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153): 561-566.
8. Rodig SJ, Shapiro GI. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs. 2010;11(12): 1477-1490.
9. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378-381.
10. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190-1203.
11. Ordóñez NG. Thyroid transcription factor-1 is not expressed in squamous cell carcinomas of the lung: an immunohistochemical study with review of the literature. Appl Immunohistochem Mol Morphol. 2012;20(6):525-530.
12. Ordóñez NG. Value of thyroid transcription factor-1 immunostaining in tumor diagnosis: a review and update. Appl Immunohistochem Mol Morphol. 2012;20(5):429-444.
13. Ordóñez NG. Napsin A expression in lung and kidney neoplasia: a review and update. Adv Anat Pathol. 2012;19(1):66-73.
14. Wang F, Flanagan J, Su N, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2012;14(1): 22-29.
15. Wang H, Su N, Wang L-C, et al. Quantitative ultrasensitive bright-field RNA in situ hybridization with RNAscope. Methods Mol Biol. 2014;1211:201-212.
16. Timek DT, Shi J, Liu H, Lin F. Arginase-1, HepPar-1, and glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens. Am J Clin Pathol. 2012; 138(2):203-210.
17. Lin F, Shi J, Liu H, et al. Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma-with implication of their roles in early tumorigenesis. Am J Surg Pathol. 2008;32(1):78-91.
18. Carter JM, Caron BL, Dogan A, Folpe AL. A novel chromogenic in situ hybridization assay for FGF23 mRNA in phosphaturic mesenchymal tumors. Am J Surg Pathol. 2015;39(1):75-83.
19. Zhang K, Deng H, Cagle PT. Utility of immunohistochemistry in the diagnosis of pleuropulmonary and mediastinal cancers: a review and update. Arch Pathol Lab Med. 2014;138(12):1611-1628.
20. Lok T, Chen L, Lin F, Wang HL. Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma. Hum Pathol. 2014;45(2):394-400.
21. Schache AG, Liloglou T, Risk JM, et al. Validation of a novel diagnostic standard in HPV-positive oropharyngeal squamous cell carcinoma. Br J Cancer. 2013;108(6):1332-1339.
22. Bishop JA, Ma XJ, Wang H, et al. Detection of transcriptionally active high risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method. Am J Surg Pathol. 2012; 36(12):1874-1882.
23. Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2014;94(1):107-116.
24. Vassilakopoulou M, Togun T, Dafni U, et al. In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients. PLoS One. 2014;9(6):e99131.
25. Kim MA, Jung JE, Lee HE, Yang HK, Kim WH. In situ analysis of HER2 mRNA in gastric carcinoma: comparison with fluorescence in situ hybridization, dual-color silver in situ hybridization, and immunohistochemistry. Hum Pathol. 2013;44(4):487-494.